{"id":"https://openalex.org/W4310103271","doi":"https://doi.org/10.1182/blood-2022-159193","title":"Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)","display_name":"Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310103271","doi":"https://doi.org/10.1182/blood-2022-159193"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-159193","doi":"https://doi.org/10.1182/blood-2022-159193","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-159193","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013969487","display_name":"Maximilian F. Stahl","orcid":"https://orcid.org/0000-0002-1299-5901","observed_orcids":["https://orcid.org/0000-0002-1299-5901"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maximilian F. Stahl","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066213142","display_name":"Gerard T. Giblin","orcid":"https://orcid.org/0000-0002-7452-5526","observed_orcids":["https://orcid.org/0000-0002-7452-5526"]},"institutions":[{"id":"https://openalex.org/I2803071314","display_name":"Mater Misericordiae University Hospital","ror":"https://ror.org/040hqpc16","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I2803071314"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Gerard Giblin","raw_affiliation_strings":["2Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland","institution_ids":["https://openalex.org/I2803071314"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100770937","display_name":"Yiwen Liu","orcid":"https://orcid.org/0000-0002-7982-7996","observed_orcids":["https://orcid.org/0000-0002-7982-7996"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiwen Liu","raw_affiliation_strings":["3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J DeAngelo","raw_affiliation_strings":["4Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard M. Stone","raw_affiliation_strings":["4Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013721199","display_name":"Eric S. Winer","orcid":"https://orcid.org/0000-0002-4515-8245","observed_orcids":["https://orcid.org/0000-0002-4515-8245"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric S. Winer","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047939331","display_name":"Martha Wadleigh","orcid":"https://orcid.org/0000-0002-8191-1708","observed_orcids":["https://orcid.org/0000-0002-8191-1708"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martha Wadleigh","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029501645","display_name":"Coleman R. Lindsley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Coleman Lindsley","raw_affiliation_strings":["5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049059619","display_name":"Shai O. Shimony","orcid":"https://orcid.org/0000-0001-7245-9652","observed_orcids":["https://orcid.org/0000-0001-7245-9652"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shai Shimony","raw_affiliation_strings":["5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012198249","display_name":"Kevin M. Copson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Copson","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112778923","display_name":"Anne Laure Charles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Charles","raw_affiliation_strings":["6Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001986733","display_name":"Anju Nohria","orcid":"https://orcid.org/0000-0002-7113-1118","observed_orcids":["https://orcid.org/0000-0002-7113-1118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anju Nohria","raw_affiliation_strings":["7Brigham Women's Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Brigham Women's Health, Boston, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023296232","display_name":"Marlise Rachael Luskin","orcid":"https://orcid.org/0000-0002-5781-4529","observed_orcids":["https://orcid.org/0000-0002-5781-4529"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marlise R. Luskin","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.27944013,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"6067","last_page":"6068"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.008200000040233135,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11638","display_name":"Cardiac tumors and thrombi","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anthracycline-induced-cardiotoxicity","display_name":"anthracycline cardiotoxicity","score":0.9369999766349792},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.8730000257492065},{"id":"https://openalex.org/keywords/7-3-regimen","display_name":"7+3 regimen","score":0.7919999957084656},{"id":"https://openalex.org/keywords/cpx-351","display_name":"CPX-351","score":0.8360000252723694},{"id":"https://openalex.org/keywords/liposomal-daunorubicin","display_name":"liposomal daunorubicin","score":0.9259999990463257},{"id":"https://openalex.org/keywords/left-ventricular-ejection-fraction","display_name":"left ventricular ejection fraction","score":0.8700000047683716},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.6299999952316284},{"id":"https://openalex.org/keywords/npm1","display_name":"NPM1","score":0.6859999895095825},{"id":"https://openalex.org/keywords/dnmt3a","display_name":"DNMT3A","score":0.800000011920929},{"id":"https://openalex.org/keywords/tp53","display_name":"TP53","score":0.5559999942779541},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.6190000176429749},{"id":"https://openalex.org/keywords/risk-factors","display_name":"risk factors","score":0.36000001430511475},{"id":"https://openalex.org/keywords/echocardiographic-screening","display_name":"echocardiographic screening","score":0.6399999856948853},{"id":"https://openalex.org/keywords/cumulative-anthracycline-dose","display_name":"cumulative anthracycline dose","score":0.656000018119812}],"concepts":[{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.7988522052764893},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7449146509170532},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6336668729782104},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5830042362213135},{"id":"https://openalex.org/C2778797674","wikidata":"https://www.wikidata.org/wiki/Q847583","display_name":"Cardiomyopathy","level":3,"score":0.540164053440094},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5209685564041138},{"id":"https://openalex.org/C2776611710","wikidata":"https://www.wikidata.org/wiki/Q16888295","display_name":"Induction chemotherapy","level":3,"score":0.5201297402381897},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4986100196838379},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.479581743478775},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4622812569141388},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.4476637840270996},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3559436798095703},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27897441387176514},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.16663900017738342},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-159193","doi":"https://doi.org/10.1182/blood-2022-159193","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-159193","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4384028208","https://openalex.org/W3183721761","https://openalex.org/W2890103576","https://openalex.org/W2764064848","https://openalex.org/W2973179055","https://openalex.org/W1992645923","https://openalex.org/W4412548293","https://openalex.org/W1571940374","https://openalex.org/W2263928264","https://openalex.org/W2891118980"],"abstract_inverted_index":{"Introduction:":[0],"Anthracycline":[1],"induced":[2,12],"cardiomyopathy":[3],"(CMP)":[4],"is":[5,32,58,76,96,617],"a":[6,64,284,478,483,546,551,597,649],"concern":[7],"in":[8,103,271,327,364,460,489,565,639,648],"AML":[9,113,244],"patients":[10,229,313,461],"(pts)":[11],"with":[13,41,121,262,314,355,368,462,550,608,624],"\"7+3\u201d":[14],"(7":[15,410],"days":[16,21],"of":[17,22,44,216,223,334,342,353,477,487,527,538,556,559,591,596,635],"cytarabine":[18],"and":[19,51,83,136,149,188,207,249,257,263,308,315,336,424,431,439,499,520,584],"3":[20,269],"an":[23,276,324,349,360,376,389,405,446,471,534,578,609],"anthracycline)":[24],"or":[25,123],"liposomal":[26],"cytarabine/daunorubicin":[27],"(CPX-351,":[28],"Vyxeos).":[29],"However,":[30,363,643],"it":[31,75,95,620],"not":[33,62,97,374,387,403,417,444,469,576,589,602],"well":[34],"understood":[35],"(i)":[36,134],"how":[37,53],"common":[38],"anthracycline":[39,81,92,109,251,296,441,450,586,613,631,636],"CMP":[40,49,57,162,234,319,347,358,371,382,452,488,632],"the":[42,59,79,131,143,380,383,392,400,572],"availability":[43],"routine":[45],"echocardiography":[46],"for":[47,61,91,108,283,312,386,402,449,474,533,575,612,630],"baseline":[48],"screening":[50],"(ii)":[52,150],"often":[54],"post":[55,137,217,232,265,301,317,329,345,356,369,592],"induction":[56,125,138,161,218,233,258,266,281,298,302,318,330,346,357,370,593,638],"reason":[60,385,401,574],"pursuing":[63,388,404],"potentially":[65,622],"curative":[66],"allogeneic":[67],"stem":[68],"cell":[69],"transplant":[70],"(allo-SCT).":[71],"In":[72,391,429,545],"addition,":[73],"while":[74,198],"known":[77,98],"that":[78],"cumulative":[80,250,440,585],"dose":[82,252,442,587],"preexisting":[84],"left":[85,144],"ventricular":[86,145],"dysfunction":[87],"are":[88],"risk":[89,107,437,448,473,486,582,611,629],"factors":[90,438,583],"mediated":[93,110,451],"CMP,":[94,475,563,594],"whether":[99],"mutations":[100,457,540],"recurrently":[101],"mutated":[102,641],"myeloid":[104,456,604],"neoplasms":[105],"predict":[106,445,470],"CMP.":[111,219,267,614],"Methods:":[112],"pts":[114,225,261,270,343,354,367,560,568],"treated":[115],"at":[116,627],"Dana-Farber":[117],"Cancer":[118],"Institute":[119],"(2014-2022)":[120],"7+3":[122],"Vyxeos":[124],"were":[126,192,201,226,238,399,588],"included":[127],"if":[128],"they":[129],"met":[130],"following":[132],"criteria:":[133],"pre":[135,280],"chemotherapy":[139],"echocardiogram":[140],"to":[141,158,213,290,294,323,332,516],"assess":[142],"ejection":[146],"fraction":[147],"(LVEF)":[148],"comprehensive":[151],"next":[152],"generation":[153],"sequencing":[154],"was":[155,163,211,304,379,571,606],"obtained":[156],"prior":[157,246,254],"treatment.":[159],"Post":[160],"defined":[164],"as":[165,194,203,619],"LVEF":[166,278,303,328,554],"<":[167],"50%.":[168],"We":[169],"recorded":[170],"cardiovascular":[171,436,581],"comorbidities":[172],"including":[173,407],"hypertension":[174],"(HTN),":[175],"diabetes":[176],"mellitus":[177],"(DM),":[178],"hyperlipidemia":[179],"(HLD),":[180],"coronary":[181],"artery":[182],"disease":[183,187,413],"(CAD),":[184],"severe":[185],"valvular":[186],"smoking.":[189],"Continuous":[190],"variables":[191,200],"summarized":[193],"median":[195],"(range,":[196],"R),":[197],"categorical":[199],"reported":[202],"frequency":[204],"(percentage).":[205],"Univariable":[206],"multivariable":[208,432,500],"regression":[209],"analysis":[210,501],"performed":[212],"identify":[214],"predictors":[215],"Results:":[220],"A":[221],"total":[222],"422":[224],"included;":[227],"37":[228],"(8.8%)":[230],"developed":[231,561],"(Table":[235,453],"1).":[236],"There":[237],"no":[239],"statistical":[240],"differences":[241],"between":[242,260],"age,":[243,434],"subtype,":[245],"cancer":[247,255],"therapy":[248,256],"(for":[253],"chemotherapy)":[259],"without":[264,316,344],"Only":[268],"this":[272,321,570,644],"cohort":[273],"(0.7%)":[274],"had":[275],"abnormal":[277],"(<50%)":[279],"arguing":[282,532],"highly":[285],"preselected":[286],"pt":[287,548],"population":[288,549],"thought":[289],"be":[291],"fit":[292],"enough":[293],"receive":[295,375],"containing":[297],"chemotherapy.":[299],"The":[300],"43%":[305],"(R":[306,310],"20-48%)":[307],"60%":[309],"50-75%)":[311],"(p<0.001);":[320],"corresponded":[322],"absolute":[325],"decrease":[326],"compared":[331],"pre-induction":[333,553],"-18%":[335],"-3%,":[337],"respectively":[338],"(p<0.001).":[339,362],"While":[340,455,580],"73%":[341],"received":[348,359],"allo-SCT,":[350],"only":[351,365,566],"46%":[352],"allo-SCT":[361,377,406,416],"4/20":[366],"who":[372],"did":[373,443,468],"(20%)":[378],"emergent":[381],"sole":[384,573],"allo-SCT.":[390,579],"other":[393,396,425,603],"16/20":[394],"pts,":[395],"medical":[397],"reasons":[398,426],"sepsis/fungal":[408],"infection":[409],"pts),":[411,415,557],"active":[412],"(3":[414],"indicated":[418],"given":[419],"favorable":[420],"genetics":[421],"(2":[422],"pts)":[423],"(4":[427],"pts).":[428,642],"univariable":[430,490],"analysis,":[433],"sex,":[435],"increased":[447,472,485,610],"2).":[454],"commonly":[458],"seen":[459],"clonal":[463],"hematopoiesis":[464],"(DNMT3A,":[465],"TET2,":[466],"ASXL1)":[467],"presence":[476,595],"JAK2":[479,509,539,598,640],"V617F":[480,510],"mutation":[481,600],"predicted":[482],"significantly":[484],"(hazard":[491],"rate":[492],"[HR]":[493],"5.57,":[494],"95%":[495,504],"CI:":[496,505],"1.14-22.1,":[497],"p=0.019)":[498],"(HR":[502],"5.91,":[503],"1.18-24.1,":[506],"p=0.017).":[507],"Interestingly,":[508],"transgenic":[511],"mice":[512],"have":[513],"been":[514],"shown":[515],"develop":[517],"cardiac":[518,542],"hypertrophy":[519],"collagen":[521],"fibrosis":[522],"(Shi":[523],"et":[524],"al.":[525],"Journal":[526],"Hematology":[528],"&":[529],"Oncology":[530],"2014)":[531],"underlying":[535],"biological":[536],"effect":[537],"on":[541],"function.":[543],"Conclusions:":[544],"selected":[547],"normal":[552],"(99.3%":[555],"8%":[558],"post-induction":[562],"however,":[564],"4/123":[567],"(3%)":[569],"receiving":[577],"predictive":[590],"V617V":[599],"(but":[601],"mutations)":[605],"associated":[607],"This":[615],"association":[616],"intriguing":[618],"could":[621],"help":[623],"patient":[625,651],"selection":[626],"higher":[628],"(e.g.":[633],"consideration":[634],"free":[637],"will":[645],"require":[646],"validation":[647],"larger":[650],"cohort.":[652],"Figure":[653],"1View":[654,657],"largeDownload":[655,658],"PPTFigure":[656],"PPT":[659],"Close":[660],"modal":[661]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-11-30T00:00:00"}